{
    "organizations": [],
    "uuid": "7d88fe9d1bc03fc4b3a510b6b52c990abdb8dbbd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immune-pharmaceuticals-provides-pi/brief-immune-pharmaceuticals-provides-pipeline-update-idUSASC0A3DF",
    "ord_in_thread": 0,
    "title": "BRIEF-Immune Pharmaceuticals Provides Pipeline Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 23 (Reuters) - Immune Pharmaceuticals Inc:\n* IMMUNE PHARMACEUTICALS PROVIDES A PIPELINE UPDATE * IMMUNE PHARMACEUTICALS INC - CONTINUE DISCUSSIONS WITH PARTIES POTENTIALLY INTERESTED IN ACQUIRING CERTAIN OF CYTOVIAâ€™S ASSETS\n* IMMUNE PHARMACEUTICALS INC - HAS BEGUN PLANNING FOR A RANDOMIZED, CONTROLLED PHASE 2/3 TRIAL TO LAUNCH IN 2019 FOR BERTILIMUMAB\n* IMMUNE PHARMACEUTICALS - PREPARING FOR MEETINGS WITH FDA, EMA LATER IN YEAR TO DISCUSS PLANNED PHASE 2/3 STUDY, MANUFACTURING PLANS FOR BERTILIMUMAB\n* IMMUNE PHARMACEUTICALS INC - CURRENTLY PLANNING A TOXICITY STUDY TO BEGIN IN Q3 FOR NANOCYCLO\n* IMMUNE PHARMACEUTICALS INC - EXPECTS TO COMMENCE PLANNED PROOF-OF-CONCEPT CLINICAL TRIAL LATE IN Q4 2018 OR EARLY Q1 2019 FOR NANOCYCLO Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-23T21:27:00.000+03:00",
    "crawled": "2018-05-24T20:35:53.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "immune",
        "pharmaceutical",
        "inc",
        "immune",
        "pharmaceutical",
        "provides",
        "pipeline",
        "update",
        "immune",
        "pharmaceutical",
        "inc",
        "continue",
        "discussion",
        "party",
        "potentially",
        "interested",
        "acquiring",
        "certain",
        "cytovia",
        "asset",
        "immune",
        "pharmaceutical",
        "inc",
        "begun",
        "planning",
        "randomized",
        "controlled",
        "phase",
        "trial",
        "launch",
        "bertilimumab",
        "immune",
        "pharmaceutical",
        "preparing",
        "meeting",
        "fda",
        "ema",
        "later",
        "year",
        "discus",
        "planned",
        "phase",
        "study",
        "manufacturing",
        "plan",
        "bertilimumab",
        "immune",
        "pharmaceutical",
        "inc",
        "currently",
        "planning",
        "toxicity",
        "study",
        "begin",
        "q3",
        "nanocyclo",
        "immune",
        "pharmaceutical",
        "inc",
        "expects",
        "commence",
        "planned",
        "clinical",
        "trial",
        "late",
        "q4",
        "early",
        "q1",
        "nanocyclo",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}